In the ninth episode, Nicholas and Lana unpack several longevity launches making waves, and why regulatory clearance, novelty, and clinical data are 3 separate things brands shouldn't blur together.

Why responsible innovation means asking whether yesterday's formulations still reflect today's best science—not just launching the next new ingredient.

TriNutra is presenting new data on its standardized black seed oil ingredient at SupplySide Global, adding to a growing body of research on how gut bacteria and the body's stress response may influence each other.

A randomized crossover trial finds that formulation, not just dose, determines how much of the hops-derived compound xanthohumol actually reaches the bloodstream.

A new 12-week trial adds controlled data to a question that matters for manufacturers positioning creatine beyond sports nutrition: does its muscle-building evidence hold up in adults over 45, including those not following a structured exercise program?

A randomized, crossover trial found that ThymoDream, a standardized black cumin seed oil, raised endogenous melatonin levels and improved several sleep measures over 7 nights, with lower reported daytime sleepiness than synthetic melatonin.

The proposed notification requirement is straightforward, but its legal and commercial consequences are not.

The company plans to unveil a clinically studied ingredient on opening day and host a longevity session alongside its cognitive, mobility, and metabolic health portfolio.